A Phase 1 Study of IPI-926 in Patients With Advanced and/or Metastatic Solid Tumor Malignancies
The primary objectives of the study are:

* To determine the safety and the maximum tolerated dose (MTD) of IPI-926
* To examine the pharmacokinetic parameters of IPI-926 and its characterized major metabolite(s)
* To recommend a dose and schedule of IPI-926 for subsequent studies
Neoplasms
DRUG: IPI-926
To determine the safety and the maximum tolerated dose (MTD) of IPI-926, 6mths to 1 year
To evaluate the anti-tumor activity of IPI-926, 6mths to 1 year
Study IPI-926-01 is a Phase 1, open-label, dose-escalation study in patients with advanced and/or metastatic solid tumor malignancies.